References
- Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21:407–421
- Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302:758–766
- Morshedi RG, Bettis DI, Moshirfar M, et al. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocul Immunol Inflamm. 2012;20:266–272
- Tugal-Tutkun I, Onal S, Garip A, et al. Bilateral acute iris transillumination. Arch Ophthalmol. 2011;129:1312–1319
- Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2009;23:2260–2262
- Willermain F, Deflorenne C, Bouffioux C, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2010;24:1419; author reply, 20
- Bringas Calvo R, Iglesias Cortinas D. [Acute and bilateral uveitis secondary to moxifloxacin]. Arch Soc Esp Oftalmol. 2004;79:357–359
- Hinkle DM, Dacey MS, Mandelcorn E, et al. Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol. 2012;31:111–116
- Butler NJ, Suhler EB. Levofloxacin-associated panuveitis with chorioretinal lesions. Arch Ophthalmol. 2012;130:1342–1344
- Population Data British Columbia. Discharge abstract database. www.popdata.bc.ca/data/internal/health/dad (accessed January 25, 2013)
- Ministry of Health. Medical Services Plan of British Columbia. www.health.gov.bc.ca/msp/index.html (accessed January 25, 2013)
- British Columbia Ministry of Health. PharmaNet. www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html (accessed January 25, 2013)
- Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305:2525–2531
- Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307:1414–1419
- Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012;184:E431–E434
- Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19:205–213
- Fraunfelder FW. Drug-induced ocular inflammatory diseases. Drugs Today (Barc). 2007;43:117–123
- Tinley C, Van Zyl L, Grotte R. Poststreptococcal syndrome uveitis in South African children. Br J Ophthalmol. 2012;96:87–89
- Birnbaum AD, Jiang Y, Vasaiwala R, et al. Bilateral simultaneous-onset nongranulomatous acute anterior uveitis: clinical presentation and etiology. Arch Ophthalmol. 2012;130:1389–1394